Senator Ron Wyden (D-Oregon) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had bought between $50,001 and $100,000 ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

Eli Lilly and Company (NYSE:LLY) is a developer, explorer, and marketer of human pharmaceuticals. The company offers a wide range of products including Humalog, Zepbound for obesity, oncology ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Lilly’s Humalog and Trulicity have been major revenue drivers. Eli Lilly and Company (NYSE:LLY) was also the first to mass-produce both the polio vaccine and insulin. More recently, the company ...

In the field of diabetes care, Lilly’s Humalog and Trulicity have been major revenue drivers. Eli Lilly and Company (NYSE:LLY) was also the first to mass-produce both the polio vaccine and insulin.

Indianapolis-based drugmaker Eli Lilly and Company has announced price reductions ... effective as of Q4 2023. Both Humalog and Insulin Lispro Injection are fast-acting insulins, they are used ...

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is poised for a breakout by FY2025.

1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the ...